25HC3S Dosing Regimen for Severe Alcoholic Hepatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for alcoholic hepatitis, such as corticosteroids, have inconsistent results, pose infection risks, and are unsuitable for certain patients, while liver transplantation is often not feasible due to high mortality rates before meeting criteria, necessitating an improved therapeutic approach.
Innovation Solution
Administering low doses of 5-cholesten-3,25-diol, 3-sulfate (25HC3S) or its salts, in a low frequency and limited number of doses, effectively treats alcoholic hepatitis, even in patients with severe liver dysfunction, as characterized by specific diagnostic criteria like MELD score.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroids are used to treat severe alcoholic hepatitis, then liver function improves, but infection risk increases and patient compliance decreases
Solution Approach 1:
The patent changes the chemical parameter by using 25HC3S instead of conventional corticosteroids, and adjusts the dosing parameter by using lower doses (30-150 mg) with extended intervals (every 1-4 weeks) compared to daily corticosteroid administration, thereby reducing infection risk while maintaining therapeutic effect
Solution Approach 2:
The patent employs a short-acting lipid-based compound (25HC3S) that is metabolized quickly, replacing long-acting corticosteroids, allowing for lower total doses and reduced cumulative side effects including infection risk
2Reliability
If corticosteroids are administered daily at high doses, then therapeutic effect is achieved, but patient compliance decreases
Solution Approach 1:
The patent implements periodic action by administering 25HC3S at extended intervals (every 1-4 weeks) rather than daily, which simplifies the regimen and improves patient compliance while maintaining therapeutic effectiveness through cumulative dosing over time
Solution Approach 2:
The patent uses lower individual doses (30-150 mg) that may seem insufficient for acute treatment, but achieves therapeutic effect through multiple doses spaced over time, relying on the cumulative effect rather than high acute dosing
3Reliability
If liver transplantation is performed for severe alcoholic hepatitis, then curative treatment is achieved, but mortality risk increases and timing is delayed
Solution Approach 1:
The patent provides preliminary action by offering 25HC3S treatment to severe AH patients before they meet the 6-month abstinence criteria for transplantation, thereby treating the condition earlier and potentially avoiding the high mortality period before transplant eligibility
4Reliability
If high dose and frequent dosing of corticosteroids is used, then therapeutic efficacy is achieved, but total substance consumption increases
Solution Approach 1:
The patent changes the dosing parameters by using lower individual doses (30-150 mg of 25HC3S) with extended intervals (every 1-4 weeks), resulting in lower total substance consumption compared to daily high-dose corticosteroid therapy while maintaining therapeutic efficacy
Data Source
AI summary
Methods of treating alcoholic hepatitis (AH) are provided. For instance, the methods may comprise administering 5-cholesten-3,25-diol, 3-sulfate (25HC3S) or a salt thereof.